Pfizer Inc. (PFE.NYSE) wil cease vaccine commercial operations in China after the government did not renew its import license for the only vaccine the company sells there, Bloomberg reported, citing a statement from the company. While the vaccine, Prevenar, is the only one for pneumococcal disease approved in China for children under two, no data proves infants have a high infection rate, said Shi Lichen, a manager at Beijing Dingchen Medical Consultancy. A company spokesperson said Pfizer was in the process of working with the government to get a newer version of the drug onto the market.
You must log in to post a comment.
Yes, I would like to receive emails from China Economic Review. (You can unsubscribe anytime)
Copyright © 2018 SinoMedia Group Limited All rights reserved